Winkler, B <br/><br/>
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.  [electronic resource] 

 -  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology  Jan 2002 
 - 30-6 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0954-7894 
<br/><br/><label>Standard No.: </label>10.1046/j.0022-0477.2001.01214.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intranasal<br/>Allergens--administration & dosage<br/>Animals<br/>Antibody Formation<br/>Antigens, Plant<br/>Cell Division<br/>Cytokines--metabolism<br/>Female<br/>Hypersensitivity, Immediate--complications<br/>Immune Tolerance<br/>Immunization<br/>Immunotherapy--methods<br/>Inflammation--etiology<br/>Lung--metabolism<br/>Mice<br/>Mice, Inbred BALB C<br/>Plant Proteins--therapeutic use<br/>Pollen<br/>Recombinant Proteins--administration & dosage<br/>Respiratory Mucosa--immunology<br/>Respiratory Tract Diseases--etiology<br/>Spleen--metabolism<br/>Trees